×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
AI, Virtual Control Groups, and Organoids: How New Technologies are Being Developed to Align With Ethical Principles in Animal Research
Session Chair(s)
Lindsay McNair, MD, MPH, MS
Principal Consultant
Equipoise Consulting, United States
This session will review the 3Rs (replacement, refinement, reduction) of animal use in non-clinical drug development research, and how new technologies including AI, Victorian Clinical Genetics Services (VCGs) and organoids are introducing innovative ways to meet these ethical principles.
Learning Objective : Understand the “3Rs” (replacement, refinement, reduction) of ethical animal use in non-clinical drug development research; Review how new technologies including AI, VCGs and organoids are being explored to follow these ethical principles as part of the overall drug development program.
Speaker(s)
How New Technologies are Being Developed to Align With Ethical Principles in Animal Research
Julie Frearson, PhD
Charles River Laboratories, United States
Senior Vice President, Chief Scientific Officer
Panelist
Szczepan Baran
Chief Barks and Purrs Officer, United States
Tech4Pets
Have an account?